trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Rituximab is associated with increased risks of serious infections due to the depletion of B cells.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
2 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Rituximab is associated with increased risks of serious infections due to the depletion of B cells?

Yes. Rituximab depletes B cells, leading to hypogammaglobulinemia and an increased risk of serious infections.

Verdict: SUPPORTED · 2 sources for, 0 against · Last checked

The analysis

The retrieved papers consistently support the claim that rituximab is associated with infection risks linked to B-cell depletion and subsequent hypogammaglobulinemia, without any papers refuting this well-established clinical finding.

Evidence for · 2
Real-world comparison of anti-CD20 therapies: efficacy, infections, and immune profiles in a German cohort.
2026
This study demonstrates that rituximab treatment leads to B-cell depletion and is associated with the early development of hypogammaglobulinemia and infection-related concerns.
Get citation
J, S., M, B., L, G., L, T., K, F., R, U., EA, H., GO, N., HF, H., O, S., M, P., SG, M., M, S., S, G., & M, F. (2026). Real-world comparison of anti-CD20 therapies: efficacy, infections, and immune profiles in a German cohort.. doi.org. https://doi.org/10.3389/fimmu.2026.1738865

See more details
More for · 1
Age, Low Immunoglobulin G, and M Serum Levels Predict Infections in People With AQP4-IgG+ NMOSD Treated With Rituximab-A Multicenter Cohort Study From the German Neuromyelitis Optica Study Group (NEMOS).
2026
This multicenter cohort study establishes that infections are a significant clinical concern during rituximab treatment, noting that hypogammaglobulinemia serves as a key predictor of infection risk.
Get citation
D, E., M, H., J, H., P, S., K, R., C, S., M, R., K, F., C, S., I, S., MW, H., K, G., S, J., I, V., M, G., T, E., C, W., J, N., F, H., M, S., B, W., A, B., C, T., V, H., O, A., I, A., J, B., FT, B., & T, K. (2026). Age, Low Immunoglobulin G, and M Serum Levels Predict Infections in People With AQP4-IgG+ NMOSD Treated With Rituximab-A Multicenter Cohort Study From the German Neuromyelitis Optica Study Group (NEMOS).. doi.org. https://doi.org/10.1111/ene.70520

What does the evidence say?

The retrieved papers consistently support the claim that rituximab is associated with infection risks linked to B-cell depletion and subsequent hypogammaglobulinemia, without any papers refuting this well-established clinical finding.

also asked as
  • Does rituximab cause a higher risk of serious infections because it depletes B cells?
  • Is rituximab linked to increased serious infection risks resulting from B cell depletion?
  • Does B cell depletion by rituximab lead to a greater risk of severe infections?
  • Are serious infections more likely with rituximab due to B cell reduction?
Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work